Novartis AG
NVS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001114448
No open-market purchases or sales by Novartis AG insiders were filed in the last 90 days; 1,626 institutions reported holding it in 13F filings for Q2 2026, worth $21.3B in total; Maverick Capital is the only superinvestor holding it.
Other share classesNVSEF
Superinvestors holding NVS, Q2 2026
1 superinvestor reports holding Novartis AG on Form 13F, worth $4.36M in total. Weight is Novartis AG's share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Maverick CapitalLee Ainslie | <0.1% | 27,789 | $4.36M | Added+82.3% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of NVS each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+82.3%)
Q1 2026
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+37.7%)
Q4 2025
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+34.7%)
Q3 2025
1 superinvestor holding at quarter end
Q3 2024
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital
Q2 2024
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+297.1%)
Q1 2024
1 superinvestor holding at quarter end
Q2 2021
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital